logo
Why did baked beans get recalled in Florida, North Carolina and 21 other states?

Why did baked beans get recalled in Florida, North Carolina and 21 other states?

Miami Herald07-05-2025

Recalls Why did baked beans get recalled in Florida, North Carolina and 21 other states?
Baked beans sold under the Yellowstone brand — yes, same as the TV show — have been recalled in 23 states.
In recalling 4,515 cases of Yellowstone Brown Sugar Molasses Baked Beans in 15-ounce cans, Vietti Food Group admitted the label didn't include soy, which is an allergen. That's a serious error to anyone with a soy allergy or who might be serving these beans to someone with a soy allergy.
'Individuals with an allergy or severe sensitivity to soy risk serious or life-threatening allergic reactions if they consume this product,' the Vietti-written, FDA-posted recall notice states.
The recall covers cans in the lot with 'Best If Used By Feb. 17, 2028' on the bottom. They went to stores in Florida, North Carolina, Missouri, Illinois, Kentucky, Georgia, Texas, Mississippi, Pennsylvania, Arizona, Colorado, Delaware, Iowa, Kansas, Louisiana, Michigan, New Hampshire, New York, Ohio, Oregon, Tennessee, Utah and Virginia.
Yellowstone Brown Sugar Molasses Baked Beans
FDA
If you have these baked beans and there's no chance someone with a soy allergy will eat them, carry on as usual. If there's any chance someone with a soy allergy will come in contact with them, return them to the store for a refund.
If you have questions about this recall, call Vietti Food Group at 513-682-2474 Monday-Friday from 8 a.m. to 4 p.m. CT, or email recall@zwanfood.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA Pauses Trials of Gilead HIV Combination After Safety Signal
FDA Pauses Trials of Gilead HIV Combination After Safety Signal

Bloomberg

time38 minutes ago

  • Bloomberg

FDA Pauses Trials of Gilead HIV Combination After Safety Signal

Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients. The studies were testing two experimental HIV drugs, GS-1720 and GS-4182, when given together. Gilead said the Food and Drug Administration paused the trials due to a ' safety signal ' triggered by a decrease in lymphocyte levels in some patients given the therapy. Lymphocytes are a type of white blood cell that play a critical role in the immune system's ability to fight infections.

Insmed's Drug for Rare Lung Disease Meets Main Goal in Mid-stage Trial
Insmed's Drug for Rare Lung Disease Meets Main Goal in Mid-stage Trial

Medscape

time42 minutes ago

  • Medscape

Insmed's Drug for Rare Lung Disease Meets Main Goal in Mid-stage Trial

(Reuters) -Insmed said on Tuesday that its experimental drug significantly reduced blood pressure in the lungs and improved exercise capacity in patients in a mid-stage study, sending shares of the company up 26% in premarket trading. The drug, treprostinil palmitil, is a once-daily therapy that is inhaled through a device. The 102-patient study found that the drug helped reduce blood pressure in the patients' lungs by 35%, compared with a placebo. It also helped improve the patients' ability to walk by an average of 35.5 meters and reduced levels of a protein associated with heart stress by 60%. The company plans to discuss the trial data with the U.S. Food and Drug Administration and initiate a late-stage trial for the drug in patients with pulmonary arterial hypertension (PAH) — a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure - in early 2026. Insmed also plans to start a separate late-stage trial for the drug in patients with pulmonary hypertension associated with interstitial lung disease - a condition where lung scarring leads to high blood pressure in the lung arteries - before the end of 2025. Current treatment options available to treat PAH are Merck's injectable Winrevair and Liquidia's inhaled Yutrepia. (Reporting by Kamal Choudhury in Bengaluru; Editing by Maju Samuel) Reuters Health Information © 2025 Reuters Ltd.

Honey Recall Map Shows Warnings Issued to Customers in 7 States
Honey Recall Map Shows Warnings Issued to Customers in 7 States

Newsweek

timean hour ago

  • Newsweek

Honey Recall Map Shows Warnings Issued to Customers in 7 States

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Food and Drug Administration (FDA) has announced its classification of a recall of certain Comvita honey products, affecting seven states. Comvita, a California-based company, recalled three of its manuka honey products last month as the induction seal was not properly fitted, meaning the product was leaking on the packaging. Newsweek has contacted Comvita outside of regular working hours via email for comment. File photo: a teaspoon with a jar full of honey. File photo: a teaspoon with a jar full of honey. Oliver Berg/dpa via AP Why It Matters Maintaining packaging standards is important as it can make consumers feel more assured that companies have followed regulatory guidance more closely, and ensured their products are properly manufactured and controlled. Given that many Americans are concerned about food safety and food recalls, maintaining standards and regulations are even more important if brands want to establish consumer trust. What To Know The affected products include: Comvita's Manuka Honey + Lion's Mane for Focus (355g), with lot codes 34828522 and 34835584, and expiration dates of January 21, 2026 and February 21, 2026 respectively Comvita's Manuka Honey + Cordyceps for Energy (355g) with lot codes 34828523 and 34835585, and expiration dates of January 22, 2026 and February 25, 2026 respectively Comvita's Manuka Honey + Reishi (355g) with lot codes 34828521 and 34835574, and expiration dates of January 21, 2026 and February 24, 2026 respectively There were 2,730 units sold of each product, to various states including Colorado, Arizona, Texas, Maryland, Florida, California, and Georgia. Comvita initiated the recall on May 23, and the FDA announced its classification of the recall on June 9. The FDA classification of the recall was a Class II, meaning it is a situation "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." What People Are Saying Professor Byron Chaves, a professor and food safety extension specialist in the department of Food Science and Technology at the University of Nebraska-Lincoln, told Newsweek: "An induction seal is a protective seal commonly found on food containers, like jars or bottles, just under the cap. It's created using heat to attach a foil liner to the container's opening, forming a tight, tamper-evident seal. This helps prevent leaks, keeps the product fresh, and shows if the package has been opened." He added: "If an induction seal isn't properly applied, it can lead to leaks, contamination, and reduced shelf life. It also means the package may not show evident signs of tampering, which can raise safety concerns. In some cases, it could lead to regulatory issues or loss of consumer trust if the product appears unsafe or poorly sealed." What Happens Next Consumers are advised not to consume the affected products and return them to the place of purchase for a refund. As of June 9, the recall remains ongoing. The FDA did not specify if any illnesses had been reported in relation to the recall.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store